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High-precision, non-invasive 
anti-microvascular approach via 
concurrent ultrasound and laser 
irradiation
Zizhong Hu1,2,3, Haonan Zhang4,5, Aghapi Mordovanakis2, Yannis M. Paulus1,2, Qinghuai Liu3, 
Xueding Wang1,4 & Xinmai Yang6
Antivascular therapy represents a proven strategy to treat angiogenesis. By applying synchronized 
ultrasound bursts and nanosecond laser irradiation, we developed a novel, selective, non-invasive, 
localized antivascular method, termed photo-mediated ultrasound therapy (PUT). PUT takes 
advantage of the high native optical contrast among biological tissues and can treat microvessels 
without causing collateral damage to the surrounding tissue. In a chicken yolk sac membrane model, 
under the same ultrasound parameters (1 MHz at 0.45 MPa and 10 Hz with 10% duty cycle), PUT with 
4 mJ/cm2 and 6 mJ/cm2 laser fluence induced 51% (p = 0.001) and 37% (p = 0.018) vessel diameter 
reductions respectively. With 8 mJ/cm2 laser fluence, PUT would yield vessel disruption (90%, p < 0.01). 
Selectivity of PUT was demonstrated by utilizing laser wavelengths at 578 nm or 650 nm, where PUT 
selectively shrank veins or occluded arteries. In a rabbit ear model, PUT induced a 68.5% reduction in 
blood perfusion after 7 days (p < 0.001) without damaging the surrounding cells. In vitro experiments 
in human blood suggested that cavitation may play a role in PUT. In conclusion, PUT holds significant 
promise as a novel non-invasive antivascular method with the capability to precisely target blood 
vessels.
Angiogenesis plays a critical role in the pathogenesis of numerous pathological conditions, including cancer, 
inflammation, and eye diseases. Significant research efforts have therefore been focused on the development of 
antivascular therapies, which include anti-angiogenic and vascular targeting therapies1. Whereas anti-angiogenic 
therapy aims to inhibit the growth of new vessels, vascular targeting therapy is designed to selectively destroy 
existing vessels. For example, angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) 
signaling pathway have been developed to treat tumors and eye diseases2–10. While these treatments have proven 
to be efficacious, like other pharmaceutical approaches, the systemic administration of drugs can cause serious 
adverse effects including stroke and heart attack11,12, and patients may become drug-resistant13,14. Moreover, sev-
eral studies on cancer have shown that while there is an initial antitumor effects, relapse and progressive tumor 
growth often follows after the use of angiogenesis inhibitors2,15–17. Local administration of these pharmaceuticals, 
e.g. intravitreal injection, also carries local risks, including local infection (endophthalmitis), cataract, and retinal 
detachment.
Additional antivascular approaches include photodynamic therapy (PDT)18–21, embolotherapy22–25, antivas-
cular ultrasound therapy (AVUT)26–28, and photothermolysis29. These approaches have been developed to shut 
down or destroy existing blood vessels. Each of these methods has limitations affecting its utility, including being 
invasive in all three vascular-selective methods. PDT requires the systemic injection of photosensitizers, making 
the skin and eyes sensitive to light after the treatment. PDT may also cause burns, swelling, pain, and scarring in 
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nearby healthy tissue and if it extravasates during intravenous injection. PDT in ophthalmic applications has also 
been associated with choroidal infarction and acute, severe vision loss30.
Embolotherapy, on the other hand, is an invasive procedure involving inserting a catheter through the vas-
cular system to the origin of the vessel to be occluded, and then injecting an agent. This is performed to control 
bleeding, close fistulae or arteriovenous malformations, devascularize organs, and reduce tumors or varicoceles.
AVUT has demonstrated the capability of removing microvessels in murine tumors26–28 with the assistance 
of microbubbles, via disruption or embolization. However, similar to PDT and embolotherapy, AVUT requires 
the systemic injection of foreign particles (bubbles) into the blood stream, which leads to serious concerns of 
toxicity, efficiency, and emboli formation. In addition, very strict treatment time window is also a major concern 
in clinical adaptions of both PDT and AVUT because the circulation time of photosensitizers and microbubbles 
is limited. This limits the clinical applicability, particularly in high volume retinal practices, where PDT caused a 
significant disruption in clinic flow.
Photothermolysis is a selective therapeutic technique based on optical absorption to remove tissue. It does not 
necessarily target vasculature. By using milli- or micro-second laser pulses, photothermolysis can remove highly 
optically absorptive targets such as pigmented structures and cells. However, photothermolysis requires high laser 
energy. Because it relies on the thermal effect, clinical application of the excimer photothermolysis laser is limited 
to very superficial surface layer.
We developed, for the first time, a novel, noninvasive antivascular therapy that we call photo-mediated ultra-
sound therapy (PUT). PUT applies synchronized laser pulses and ultrasound bursts on target tissue, offering 
high-precision localized treatment of microvessels. The technique is based on controlled induction and promo-
tion of micro-cavitation activity in the target vessels. When a laser pulse is absorbed by hemoglobin, the tissue is 
excited and the photoacoustic effect occurs. The concurrent application of ultrasound significantly increases the 
likelihood of micro-cavitation in the blood vessel31. The produced cavitation can then be further enhanced and 
driven by the subsequent ultrasound pulses. The shear stresses and microjets produced by oscillating bubbles in 
a microvessel can directly impact the physiological functions of endothelial cells, red blood cells, and platelets. 
This results in vasocontraction, blood clot formation, and hemorrhage26,27,32–37. The mechanism is similar to that 
of PDT and AVUT where microvessels are also destroyed by triggering the physiological functions of endothelial 
cells, red blood cells, and platelets. However, unlike PDT and AVUT which involve either photosensitizers or 
microbubbles, PUT is totally noninvasive and agent-free.
The most important advantage of the PUT technology is high precision, which features by its high selectiv-
ity on the treatment target. For targeted treatment on microvessels, the high selectivity of PUT is achieved by 
the high endogenous optical contrast between blood and other tissues in the visible to near-infrared spectrum. 
Additionally, the laser fluence needed by PUT is very low (as low as 4 mJ/cm2, which is under the safety limit set 
by American National Standards Institute (ANSI38) for skin exposure). In comparison, laser fluence used by pho-
tothermolysis is generally larger than 1 J/cm2. As a result, PUT may offer a certain penetration depth and precise 
localization for treating microvessels beyond the skin surface. The unique advantages of PUT, which is facilitated 
by synchronized light and sound irradiation, could be enormously significant when translating the technique to 
patients.
Results
Antivascular effect of PUT on single blood vessels. A PUT system is schematically illustrated in Fig. 1. 
A laser pulse (5-ns pulse width with 10-Hz pulse repetition rate) irradiated the target blood vessel with 532 nm 
light simultaneously with an ultrasound tone burst (1 MHz, 10% duty cycle, and 10-Hz pulse repetition rate). The 
applied ultrasound burst had a negative peak pressure of 0.45 MPa, and the laser fluence varied from 2 mJ/cm2 
to 8 mJ/cm2. The treatment duration was either 4 minutes or until the target blood vessel was disrupted dur-
ing the treatment, whichever occurred first. The posterior vitelline veins (p.v. veins) in chicken yolk sac mem-
branes (embryo development day (EDD)-3) were selected as the target blood vessels because (1) they have a 
relatively uniform vessel size (150–200 μ m), and (2) they barely have branches or adjacent vessels. For reference, 
Supplementary Figure 1 shows a photograph of a chicken yolk sac membrane with the main branches of veins 
and arteries labeled.
Figure 2 shows the PUT treatment results on the p.v. veins of the chick embryo model in vivo. Figure 2a,b 
show the photographs of a p.v. vein before and after PUT. A significant reduction in the diameter of the vein was 
induced by the treatment. Figure 2c shows the quantified changes in the vein diameters before and after differ-
ent treatments, including laser-only at 20 mJ/cm2 fluence (no ultrasound), ultrasound-only at 0.45 MPa negative 
peak pressure (no laser), ultrasound and laser at 2 mJ/cm2 fluence, ultrasound and laser at 4 mJ/cm2 fluence, and 
ultrasound and laser at 6 mJ/cm2 fluence. When either laser or ultrasound was applied alone, the changes in vessel 
diameters were insignificant. When laser and ultrasound were applied concurrently (i.e. PUT) with laser fluence 
of 2 mJ/cm2, no significant change in vessel diameter was noticed after the treatment. When the laser fluence was 
increased to 4 mJ/cm2 or 6 mJ/cm2, the reductions in the vessel diameters after PUT treatment became statisti-
cally significant (p < 0.01 for both 4 mJ/cm2 and 6 mJ/cm2, for paired t-test). Figure 2d shows the relative changes 
in vein diameters [(Dbefore − Dafter)/Dbefore, where Dbefore is the vessel diameter before the treatment, and Dafter is 
the vessel diameter after the treatment]. The average reductions in the vessel diameter were 51% at 4 mJ/cm2  
(p = 0.001, paired t test) and 37% at 6 mJ/cm2 (p = 0.018, paired t test). The difference between these two reduc-
tions, however, was statistically insignificant.
The disruption of the p.v. veins, or vessel rupture, during PUT was also investigated. Figure 2e,f show pho-
tographs of a disrupted vein induced by PUT. Figure 2g shows that the disruption of a blood vessel by PUT only 
became prominent when the laser fluence was increased to or above 6 mJ/cm2, with 60% of vessel disrupted at 
6 mJ/cm2 and 90% at 8 mJ/cm2. At 4 mJ/cm2 laser fluence, the disruption rate was 10%. No blood vessel disrup-
tion occurred at either 2 mJ/cm2 laser fluence or in the control groups (i.e. ultrasound only and laser only). The 
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differences between either of the two PUT treatment groups (6 mJ/cm2 and 8 mJ/cm2) and any of the rest of 
four groups (ultrasound only, laser only, PUT at 2 mJ/cm2, and PUT at 4 mJ/cm2) were statistically significant 
(p < 0.05, Fisher’s exact test).
Selective antivascular effect of PUT on arteries and veins. PUT can selectively be used to treat arter-
ies or veins based on the absorption spectrum of hemoglobin in the visible to near-infrared spectrum. By utilizing 
the difference in optical absorption spectra between oxy-hemoglobin (HbO2) and deoxy-hemoglobin (HbR), 
PUT can selectively treat either veins or arteries. We chose two optical wavelengths, 578 nm and 650 nm, to target 
HbO2 and HbR, respectively. The ratio between the optical absorption of HbO2 and HbR (HbO2/HbR) reaches 
a local maximum of 1.42 at 578 nm, while the ratio between the optical absorption of HbR and HbO2 (HbR/
HbO2) reaches a local maximum of 10.2 at 650 nm. For chicken embryos, the oxygen saturation is opposite of 
normal adults, namely the vein has a high oxygen saturation and the artery a low oxygen saturation. The lateral 
vitelline vein (l.v. vein) is approximately 2.3 times the oxygen saturation of the lateral vitelline artery (l.v. artery)39. 
Therefore, PUT with 578-nm laser light would selectively treat l.v. veins, while PUT with 650-nm laser light would 
selectively treat l.v. arteries.
During PUT with 578-nm laser light targeting oxygenated Hb in the l.v. veins, blood vessel pairs consisting of 
a single vein and a single artery were selected as the treatment area. The applied ultrasound peak negative pressure 
was 0.25 MPa and the range of laser fluence was from 25 mJ/cm2 to 40 mJ/cm2. After 6 minutes of PUT with 35 mJ/cm2 
and 40 mJ/cm2 laser fluence, significant vein thinning was observed (p < 0.001 for paired t-test) (Fig. 3a–c; 
and Supplementary Video 1). For the treatment groups of PUT at 20 mJ/cm2 and PUT at 30 mJ/cm2, mild vein 
thinning was noted, although the changes were statistically insignificant. For the two control groups, including 
laser-only with 40 mJ/cm2 fluence and ultrasound-only, no change in the vein diameters was observed. There was 
no change in artery diameter for any group using 578-nm laser (Fig. 3c). The relative reduction in the vein diam-
eter in each group was also calculated, as shown in Supplementary Figure 2. Statistical significances were found 
when comparing the outcomes from the PUT groups with laser fluence ≥ 30 mJ/cm2 with those from the control 
groups (ultrasound only and laser only).
During PUT with 650-nm laser light targeting deoxygenated Hb in the l.v. arteries, similar blood vessel pairs 
were exposed to PUT with an ultrasound peak negative pressure of 0.45 MPa. At this wavelength, arteries were 
selectively treated. In our experiments, we noticed that the responses of arteries and veins were different after 
PUT. While veins typically decreased in size, arteries tended to develop blood clots or disrupt in addition to 
changing size. Therefore, the antivascular effect of PUT was defined as either rupture or occlusion of a blood 
vessel caused by PUT. After a 6-minute treatment, in the groups of PUT with 12 mJ/cm2 and 18 mJ/cm2 laser flu-
ence, the antivascular effects were selectively induced to arteries while the vein in each blood vessel pair remained 
unaffected (n = 10, p < 0.001, Fisher’s exact test) (Fig. 3d–f, and Supplementary Video 2). The detailed statistical 
results are shown in Supplementary Figure 3. In the two control groups, where only laser (40 mJ/cm2) or only 
ultrasound (0.45 MPa peak negative pressure) was applied, no change in either veins or arteries was observed 
(p < 0.001 and p < 0.001 when compared with PUT with 12 mJ/cm2 and 18 mJ/cm2 groups, Fisher’s exact test), as 
shown in Fig. 3f. Moreover, in the group of PUT with 12 mJ/cm2 laser fluence, 80% of arteries (8 out of 10) were 
occluded and 20% (2 of 10) were disrupted. When the laser fluence was increased to 18 mJ/cm2, 50% of arteries 
were occluded and the other 50% were disrupted.
Figure 1. System schematic. (a,b) The PUT system consisted of a laser system and a therapeutic ultrasound 
system. A function generator was trigged by the laser system to generate burst signals at 1 MHz and 10% duty 
cycle with 10-Hz pulse repetition rate. The generated bursts were amplified by a 50-dB radio frequency amplifier 
before being sent to the therapeutic ultrasound transducer. Either an optical microscope or a PeriCam PSI 
System was employed for real-time monitoring of microcirculation. (c) Each laser pulse was delivered to the 
sample to overlay the beginning phase of each ultrasound burst. (d) Photograph of the system.
www.nature.com/scientificreports/
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Figure 2. PUT on single blood vessels (veins) on chicken yolk sac membrane. (a,b) The photographs of a 
vessel before and after treatment, respectively. The vessel was treated by PUT with 0.45 MPa ultrasound negative 
peak pressure and 4 mJ/cm2 laser fluence at 532 nm. (c) Changes in blood vessel diameters after different 
treatments, including laser only (no ultrasound), ultrasound only (no laser), ultrasound and laser at 2 mJ/cm2 
fluence, ultrasound and laser at 4 mJ/cm2 fluence, and ultrasound and laser at 6 mJ/cm2 fluence. Vertical bars 
demonstrate the standard deviation. (d) The relative change of the vitelline vein diameters [(Dbefore − Dafter)/
Dbefore, where Dbefore is the diameter before treatment, and Dafter is the diameter after treatment]. It shows that 
statistical significances exist between either of the two PUT groups (4 mJ/cm2 and 6 mJ/cm2 laser fluence) and 
any of the other three groups (ultrasound only, laser only, and PUT with 2 mJ/cm2 laser fluence). (e,f) The 
photographs of a vessel disrupted by PUT with 8 mJ/cm2 laser fluence at 532 nm. (g) Rate of vessel disruption 
for each treatment group. It shows that, in comparison with other groups, the disruption rates were remarkably 
high for PUT with 6 mJ/cm2 and 8 mJ/cm2 laser fluence. The applied laser fluence for laser-only groups: 20 mJ/cm2. 
The applied ultrasound negative peak pressure: 0.45 MPa, n = 10 for each group. The treated area is circled. 
*p < 0.05; **p < 0.01, ***p < 0.001. Scale bar: 200 μ m.
www.nature.com/scientificreports/
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Figure 3. Selective treatment of veins or arteries on chicken yolk sac membranes using PUT. (a,b) The 
photographs of a pair of artery and vein before and after a treatment, respectively. PUT was performed with 
0.25 MPa ultrasound negative peak pressure and 35 mJ/cm2 laser fluence at 578 nm. (c) Changes in the vessel 
diameters after different treatments. The changes of the vessel size were only statistically significant in the veins 
of the PUT groups with 35 mJ/cm2 and 40 mJ/cm2 laser fluence (n = 10 for each group). Vertical bars indicate 
standard deviation. The laser wavelengths in (c) were all at 578 nm. (d,e) The photographs of a vein/artery pair 
before and after a treatment, respectively. The PUT treatment was performed with 0.45 MPa ultrasound negative 
peak pressure and 12 mJ/cm2 laser fluence at 650 nm. (f) The number of veins and arteries that responded to 
each treatment (n = 10 for each group). Response to treatment was defined as either rupture or occlusion of a 
blood vessel. The laser wavelengths in (f) were all at 650 nm. The treated area is circled and black arrows indicate 
the orientation of blood flow. **p < 0.01; ***p < 0.001. Scale bar: 200 μ m.
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Effect of PUT on rabbit auricular blood vessels in vivo. Rabbit auricular blood vessels were treated 
with PUT with a peak negative ultrasound pressure of 0.45 MPa and a surface laser fluence of 20 mJ/cm2 at 
584 nm. The blood perfusion rate in the treated region was monitored by a PeriCam PSI System, which is capable 
of real-time microcirculation imaging and evaluation of blood perfusion. Figure 4a,b show examples of the blood 
perfusion maps acquired before and after PUT on a rabbit ear in vivo. This example clearly demonstrates the 
diminishing of microcirculation in the treated region after PUT. To quantify the reduction in the blood perfusion, 
the perfusion rate in target microvessels was compared before and after treatment. Figure 4c shows the averaged 
reduction of perfusion rate from 5 rabbits. On average, a 63.5 ± 12% (p < 0.001, n = 5) reduction in perfusion rate 
was induced in the target microvessels. Histology confirmed that fibrin clots developed in the microvessels in the 
treated region, as shown in Fig. 4d,e, while no change occurred in the microvessels from the control groups (i.e. 
ultrasound-only and laser-only). Moreover, the histology results also demonstrate that, for all the samples treated 
with PUT, no damage was found in the surrounding tissue in rabbits euthanized either immediately following 
PUT treatment or 7-days after PUT treatment (Fig. 4f). This clearly indicates that the treatment effect of PUT 
was limited to the microvessels. In addition, the results show that PUT is effective for microvessels at a depth over 
1 mm in scattering media in vivo.
When the peak negative ultrasound pressure was increased from 0.45 MPa to 0.6 MPa while keeping the laser 
parameters the same, immediate disruption of microvessels was observed (100%) with an example result shown 
in Fig. 5A–D. Figure 5A shows the results from control groups (ultrasound-only and laser-only) while Fig. 5B 
is a photograph of a rabbit ear after PUT, demonstrating the local hemorrhage as a result of the treatment. The 
disruption of microvessels can be noticed in histology photographs after hematoxylin and eosin (H&E) stain, as 
shown in Fig. 5C,D. Clots in treated microvessels can also be found, as shown in Fig. 5E,F. In comparison, the 
results from the control groups did not show any sign of microvascular damage, as demonstrated by Fig. 5A and 
Supplementary Figure 4.
Cavitation detection during PUT. To better understand cavitation as the underlying mechanism of PUT, 
a study was performed using ex vivo human whole blood. The blood in a plastic intravenous (IV) tubing was 
treated with either ultrasound alone (control) or laser alone (control) or both laser and ultrasound (PUT). During 
the treatment, B-mode real-time ultrasound imaging was performed to visualize cavitation produced in the IV 
tubing. The results from the B-mode ultrasound imaging, as examples shown in Fig. 6, confirmed the enhanced 
cavitation activity produced by concurrently applied laser and ultrasound during PUT. Large number of bubbles 
were observed only when the laser pulses overlaid the ultrasound bursts, whereas neither the treatment involving 
only laser nor the treatment involving only ultrasound produced any detectable cavitation. We also found that 
Figure 4. Effect of PUT on a rabbit ear model in vivo and histological photographs of rabbit ear tissues. 
(a,b) Examples of the blood perfusion maps measured by a PeriCam PSI System before and after PUT on a 
rabbit ear. The perfusion map clearly demonstrated diminished blood flow in the treated microvessels (white 
arrows) after the treatment. Scale bar: 1000 μ m. (c) Averaged blood perfusion rate in the target microvessels 
before and after PUT treatment in 5 rabbits. **p < 0.01, ***p < 0.001. The applied ultrasound negative peak 
pressure was 0.45 MPa at 1 MHz with 10% duty cycle, and the laser fluence was 20 mJ/cm2 at 584 nm.  
(d) H&E stain image of rabbit ear tissue without PUT treatment, showing a normal auricular microvessel with a 
monolayer of integrated endothelial cells, basement membrane, and vascular smooth muscle (scale bar: 50 μ m). 
(e,f) H&E stain images of rabbit ear tissue immediately following and 7 days after PUT treatment (scale bar:  
50 μ m), respectively. The formation of fibrin clot (black arrow) within the lumen in an auricular vein can be 
noticed, while the surrounding cells outside the blood vessel are not damaged.
www.nature.com/scientificreports/
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the cavitation signal produced by the 570-nm laser was significantly stronger than that produced by the 650-nm 
laser at the same light fluence, because the optical absorption of the whole blood is more than 40 times higher at 
570 nm than 650 nm. This demonstrates that PUT is a “spectroscopic” treatment technique. The PUT treatment 
outcome can be controlled by applying laser at different optical wavelengths. The original real-time B-mode ultra-
sound imaging clips can be found in Supplement Video 3 and 4.
We also quantified the likelihood of cavitation by employing a passive cavitation detector (PCD). The sys-
tem schematic can be found in Supplementary Figure 5. Figure 6e shows the detected cavitation likelihood as 
functions of the ultrasound peak negative pressure and the laser fluence. When the laser fluence was 0 mJ/cm2 
(ultrasound only), or ultrasound peak negative pressure was low (less than 0.2 MPa), the likelihood of cavitation 
was nearly 0%. For any laser fluence from 15 mJ/cm2 to 30 mJ/cm2, strong cavitation was detected only when the 
ultrasound peak negative pressure was larger than 0.2 MPa which seems to be a threshold. When the ultrasound 
peak negative pressure was larger than 0.3 MPa, the likelihood of cavitation approached a constant, suggesting 
that the cavitation activity became saturated in this range. Similar types of cavitation behavior have been observed 
previously and can be explained by the availability of cavitation nuclei in the blood40. By comparing PUT and the 
controls (laser only and ultrasound only), significant increases in cavitation likelihood were observed. This study 
on well-controlled ex vivo human blood specimens suggests that the cavitation, as the underlying mechanism of 
PUT, can be reliably produced by changing the laser and the ultrasound parameters.
Discussion
We report for the first time our development of a novel technique termed PUT. PUT involves concurrently using 
safe light and safe ultrasound to achieve highly selective, precise treatment of microvessels without requiring an 
exogenous agent. The high precision of PUT is closely related to its underlying mechanism which is photoacoustic 
cavitation, or more generally, the photospallation effect41,42. When pulsed laser energy is absorbed by blood, pho-
tospallation may produce cavitation through strong, transient thermal-elastic stress41,43. Moreover, in an object 
with spherical or cylindrical shape (e.g. a blood vessel), the laser-induced photoacoustic wave can converge into 
the center and achieve a significantly high acoustic pressure and produce cavitation44, which is referred to as “cold 
bubbles” and has been observed in cells45. Unlike other use of therapeutic ultrasound and laser irradiation46–50, 
when ultrasound and laser irradiation are concurrently applied, a portion of the ultrasound waves can modulate 
the transient thermal-elastic negative stress produced through photospallation, which will increase the cavitation 
efficiency because of the greater negative pressure31. One of the key features of photoacoustic cavitation is that 
cavitation may be induced at a laser energy level that is much lower than that needed for laser thermal therapies 
(such as photothermolysis and photocoagulation) because photoacoustic cavitation is not a strictly thermal effect. 
Moreover, the synergistic application of ultrasound will further reduce the laser energy needed for cavitation.
PUT is highly selective to a treatment target (e.g. a blood vessel) and demonstrates excellent controllability 
on the desired outcome. In PUT, the cavitation in the treated tissue is initiated by the optical energy deposition 
of the laser pulses in the tissue. Strong cavitation occurs only within an area of high optical absorption where 
the ultrasound beam and laser beam overlap. The high selectivity of PUT is enabled by the endogenous optical 
Figure 5. Photographs and histological results showing vessel disruption after PUT treatment. (A) The 
photograph of a control rabbit ear treated with either laser (circled area) or ultrasound (squared area) only. 
1 MHz ultrasound-only at 0.6 MPa negative peak pressure (control) and with laser-only at 20 mJ/cm2 fluence 
at 584 nm (control). (B) The photograph of a rabbit ear after PUT treatment with 0.6 MPa ultrasound negative 
peak pressure and 20 mJ/cm2 laser fluence at 584 nm. Disruption of capillaries can be clearly noticed.  
(C–F) Histological photographs (H&E stain) showing the changes after the PUT treatment. (C) Shows detached 
endothelial cells from vessel wall (white arrow) and extravasation of erythrocytes (black triangle). (D) Shows 
disappearance of endothelial cells (white arrows). (E) Shows intravascular thrombus (black arrow).  
(F) Shows intravascular fibrin clot within the lumen and surrounding adherent red blood cells.
www.nature.com/scientificreports/
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absorption variation between various tissue types. Different tissues contain different concentrations of various 
chromophores, and have largely different optical absorption spectra which are their unique “optical fingerprints”. 
The optical fingerprint can facilitate the differentiation of tissue types with optical techniques that are highly sen-
sitive and specific. As an example, working at the wavelength(s) enabling the best optical absorption contrast of 
HbO2 or HbR over other chromophores, PUT shows the unique capability to selectively self-target either arteries 
or veins. Since blood absorbs much more optical energy than the surrounding tissue, cavitation is limited to blood 
vessels and, hence, the treatment is highly localized. Since the powers of both applied ultrasound and laser pulses 
in PUT are low, neither ultrasound-alone nor laser-alone can produce tissue damage, leaving the surrounding 
tissue intact. The excellent controllability of PUT is demonstrated by its capability to control the magnitude, 
spatial extent, and duration of cavitation produced in the target tissue (i.e. a blood vessel) by adjusting the optical 
and ultrasonic parameters. PUT can activate different treatment mechanisms in a target vessel, either through 
disruption or embolization, through precise control of the cavitation dynamics. These two mechanisms both have 
clinical value, and both can be realized by PUT operating with different laser and ultrasound parameters.
Anti-VEGF antibodies have gained great popularity to treat angiogenesis during the last decade. However, 
anti-VEGF antibodies solely neutralize the cytokine VEGF, and anti-VEGF therapy is limited51–53. This is indi-
cated by a number of studies that initial antitumor effects relapse or anti-angiogenesis yield part of patients 
with no or poor respond after the use of VEGF inhibitors2,15–17,54,55. Furthermore, frequent administration of 
Figure 6. Studying the cavitation likelihood during PUT using a B-Mode ultrasound imaging system and 
a passive cavitation detector. Human whole blood in a 3-mm diameter IV tubing was treated. (a) Ultrasound 
image when therapeutic ultrasound was applied to the IV tubing alone (ultrasound-only). (b) Ultrasound 
image when laser was applied to the IV tubing alone (laser-only). (c,d) Ultrasound images when therapeutic 
ultrasound and laser were applied concurrently (PUT). Cavitation was clearly observed when PUT was applied, 
while no cavitation was observed when either ultrasound alone or laser alone was applied. It also shows that 
cavitation activity during PUT is highly dependent on the laser wavelength. The applied ultrasound negative 
peak pressure was 0.35 MPa at 1 MHz with 4% duty cycle, and the laser fluence was 20 mJ/cm2 for both 
wavelengths (650 nm and 570 nm). (e) Cavitation likelihood detected in the human whole blood by using a 
passive cavitation detector during the PUT treatment. The laser wavelength was 570 nm.
www.nature.com/scientificreports/
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anti-VEGF drugs also was associated with direct annual medical cost56,57. Thus, developing alternative or adjunct 
therapies to the current anti-VEGF drugs has drawn increasing attention. In the current study, the findings on 
rabbit ear model in vivo suggest that PUT can treat microvessels beyond the surface of optically scattering tissues 
(depth of microvessels: ~500 μ m). Because laser energy significantly scatters in tissue, the therapeutic effects of 
photothermolysis and photocogulation are limited to very superficial surface layer58. Although the PUT not yet 
fully studied, we expect that its treatment depth would be comparable to PDT, and would be deeper than conven-
tional laser ablation, since neither PDT nor PUT relies on photo-thermal effect as in laser ablation. Additionally, 
Unlike PDT, PUT do not require the injection of exogenous agents. Therefore, most of the conditions that can be 
treated by PDT and laser ablation, including superficial tumors such as head and neck cancer59, melanoma60, and 
capillary malformation such as port-wine stain61, and retinal diseases such as polypoidal choroidal vasculopathy, 
choroidal neovascularization, and central serous chorioretinopathy62, could potentially benefit from the devel-
opment and application of PUT. In addition, current clinical applications which involve focal laser therapy of the 
macula, such as diabetic macular edema and branch retinal vein occlusions, would be other potential clinical 
applications.
To better implement PUT in a clinical setting, particularly when the target vessel is deep in soft tissue, a 
high-resolution vascular imaging will be needed to guide the treatment. Photoacoustic imaging (PAI) technique 
can be naturally combined with PUT, as PUT and PAI can share the same nanosecond pulse duration laser. PAI 
could benefit PUT treatment planning by detecting the morphological and functional information in the target 
sample, and by measuring the local light fluence and optical absorption information of vessels and background 
tissue. PAI could also help to evaluate the treatment efficacy by measuring the changes in vessel size and oxygen 
saturation in the treated vessels63. All of this information about the subsurface tissue can be acquired at excellent 
spatial and temporal resolution by PAI, and would be essential to facilitate personalized treatment and optimized 
treatment outcomes.
In summary, a hybrid ultrasound and optical technique, PUT, has been developed for antivascular therapy. 
The acute antivascular effect of the technique has been verified through the studies on a chicken embryo model 
and a rabbit ear model. PUT holds significant potential as a novel non-invasive, agent-free, highly selective, and 
highly controllable antivascular treatment.
Methods
PUT system. The schematic of the PUT system which integrates a laser system with a therapeutic ultra-
sound system is demonstrated in Fig. 1. A standard Nd:YAG pumped optical parameter oscillator (OPO) system 
(Surelite OPO PLUS, Continuum, San Jose, CA) was employed to produce laser pulses with 5-ns pulse duration 
and 10-Hz pulse repetition rate. The laser beam was delivered to the sample with its energy on the sample surface 
measured by a Nova PE25BB-SH-V2 pyroelectric head (Ophir Optronics Ltd., Jerusalem, Israel). The laser spot 
size was measured using knife-edge techniques (~8 mm in diameter) and laser intensity was carefully adjusted by 
changing the Q-switch. A 1-MHz therapeutic ultrasound transducer (H102, Sonic Concepts, Bothell, WA) was 
used to simultaneously supply ultrasound bursts with the pulsed laser. The therapeutic transducer has a geometric 
focal distance of 62.6 mm, a focal depth of 13.5 mm, and a focal width of 1.33 mm. The transducer was mounted 
to a 3-dimentional translation stage so that its focal spot can be adjusted to target the sample and overlay the laser 
spot. The peak negative ultrasound pressure was measured in situ by using a calibrated needle hydrophone (HNC-
1500, Onda, Sunnyvale, CA). Both the ultrasound transducer and samples were immersed in a water bath which 
was heated to 37.5 °C during each experiment. Either an optical microscope (M300, AmScope, Irvine, CA) or a 
PeriCam PSI System (Perimed, Järfälla, Sweden) was employed for real-time monitoring of the treatment effect.
The laser system supplied laser pulses at various power levels. Each laser pulse was delivered to the sam-
ple to overlay the beginning phase of each ultrasound burst (Fig. 1). A function generator (HP33250A, Agilent 
Technologies, Santa Clara, CA) was trigged by the laser system to produce 1 MHz bursts (10-ms long) of 10% 
duty cycle at a pulse repetition rate of 10 Hz. The signals from the function generator were then amplified by a 
50-dB radio frequency amplifier (240 L, ENI Technology, Inc., Rochester, NY) before being sent to the therapeutic 
ultrasound transducer. Cavitation occurs when the laser pulse and the beginning of the ultrasound burst are syn-
ergistically overlaid. The remaining portion of the ultrasound burst further drives the formed bubbles to stimulate 
the endothelium in the blood vessels.
In vivo chicken embryo model. Fertilized chicken eggs were obtained from a local farm (Townline Poultry 
Farm, Inc., Zeeland, MI). Culturing of chick embryo followed the protocol in the literatures64,65. In brief, eggs 
were cleaned with 70% ethanol and then hatched in a 38.0 °C humidified incubator. On embryo development 
day (EDD) 3, eggs were removed from the incubator, cleaned again with 70% ethanol, gently cracked, and then 
the chick embryos were transferred to a sterilized petri dish. The bottom of the petri dish was cut to form a 
6 cm-diameter hole which was covered by a piece of plastic wrap (Glad Cling Wrap) to allow ultrasound bursts 
to propagate through. In each group, 10 chicken embryos were included. For the experiment of single vessel 
treatment, the posterior vitelline veins (p.v. vein) were selected as the target vessels. In the experiment showing 
the selective treatment of veins or arteries, pairs of vein and artery on the yolk sac membrane were selected and 
covered by the treatment zone.
During the treatment, the flow of red blood cells in microvessels could be clearly videotaped through a 4× 
objective lens by using the optical microscope with 25 frames/s. Before and after each treatment, angiographic 
images of the chicken embryos were also captured by the optical microscopy using the 4× objective lens. Using 
the National Institutes of Health (NIH) Image J software program, the vessels widths were quantified by counting 
the pixels covered by the vessels.
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In vivo rabbit ear model. New Zealand white rabbits (2.5 to 3.0 kg, 6 to 8 weeks old, both genders) were 
acquired from the Center for Advanced Models for Translational Sciences and Therapeutics at the University of 
Michigan Medical School. All the animal handling procedures were carried out according to NIH guidelines and 
an animal protocol approved 9/3/2015 by the Institutional Animal Care and Use Committee at the University of 
Michigan, protocol number PRO00006487, PI Paulus. Briefly, each rabbit was anesthetized with 3% to 4% isoflu-
rane. Respiratory rate, heart rate, response to stimuli, and temperature were monitored. After achieving anesthe-
sia, both rabbit ears were shaved to facilitate better ultrasound coupling. Then, the rabbit was placed on a warm 
platform with one ear placed in the water tank horizontally. The ear was mounted to a custom-built holder allow-
ing flexible and reliable positioning of the treatment region. A PeriCam PSI System (Perimed, Järfälla, Sweden) 
was employed for real-time monitoring during treatment. Before and after each treatment, auricular microcircu-
lation maps were also captured by the PeriCam PSI system.
At the end of each experiment, the rabbit was euthanized with a lethal dose of isoflurane along with induction 
of bilateral pneumothorax and removal of a vital organ to ensure the animals would not revive. The auricular 
vessel segments were then dissected and placed in fixative (10% buffered formalin) solution for 3 days and then 
embedded in paraffin. The paraffin-embedded sections (thickness = 5 μ m) cut vertically to the treated vessels 
were stained with hematoxylin and eosin (H&E). Slides were deparaffinized and underwent a series of xylene and 
alcohol wash. Histology photographs were taken with an Olympus BX-51 microscope, and then analyzed by an 
experienced pathologist (Dr. John E. Wilkinson), who was blind to the treatment procedures.
Cavitation detection in ex vivo blood specimens. Human whole blood was obtained from the 
University of Michigan Blood Center. Before each treatment, a plastic intravenous (IV) tubing (inner diameter 
3 mm; outer diameter 4 mm) which is soft and optically transparent was immersed in a water bath filled with 
37.5 °C water, and placed through the focal zone of the therapeutic transducer. Blood was injected into the plastic 
IV tubing by using a syringe. The laser beam overlaid the focal zone of the ultrasound transducer. A Zonare ZS3 
ultrasound imaging system (Zonare Medical Systems, Inc., Mountain View, CA) running on the B-mode was 
used to monitor the cavitation produced in the tubing in real time.
To quantitatively evaluate cavitation events, a passive cavitation detector (PCD)66,67 was used to detect the 
signals generated from the focal zone of the therapeutic ultrasound transducer. The PCD was orientated at a 
90 degree angle from the therapeutic ultrasound transducer, and its focal zone overlaid the focal zone of the 
therapeutic ultrasound (Supplementary Figure 5). We used a broadband 20-MHz center frequency focused ultra-
sound transducer (V316, Olympus-NDT, Waltham, MA) so that the detection was more sensitive to the high 
frequency broadband noise. In addition, a high pass filter with a cutoff frequency of 5 MHz was used to minimize 
the interference signal from the 1 MHz therapeutic ultrasound. The detected signal was amplified 60 dB before 
being collected by a personal computer through a GPIB controlled digital oscilloscope (TDS540, Tektronix, Inc., 
Beaverton, OR). A cavitation event was identified when the amplitude of the detected signal was at least twice of 
that of the noise baseline.
Statistical analysis. Statistical analysis was performed using SPSS software version 19.0 (SPSS Inc., Chicago, IL). 
Paired t test was used to compare vessel size of chicken embryos and blood perfusion before and after treatment 
in the same group. The Student’s t test was applied for comparisons of independent data, and the Fisher’s exact test 
or χ2 test for comparisons of categorical data between groups. Data are expressed as mean ± standard error of the 
mean. A 2-tailed P-value of < 0.05 was used to indicate the statistical significance.
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